Growth Metrics

BeOne Medicines (ONC) Long-Term Deferred Tax (2016 - 2023)

Historic Long-Term Deferred Tax for BeOne Medicines (ONC) over the last 8 years, with Q4 2023 value amounting to $2.0 billion.

  • BeOne Medicines' Long-Term Deferred Tax fell 238.3% to $2.0 billion in Q4 2023 from the same period last year, while for Dec 2023 it was $2.0 billion, marking a year-over-year decrease of 238.3%. This contributed to the annual value of $2.0 billion for FY2023, which is 238.3% down from last year.
  • Latest data reveals that BeOne Medicines reported Long-Term Deferred Tax of $2.0 billion as of Q4 2023, which was down 238.3% from $2.1 billion recorded in Q4 2022.
  • BeOne Medicines' 5-year Long-Term Deferred Tax high stood at $2.1 billion for Q4 2022, and its period low was $30.5 million during Q1 2019.
  • Over the past 5 years, BeOne Medicines' median Long-Term Deferred Tax value was $66.0 million (recorded in 2020), while the average stood at $328.5 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first soared by 15583.34% in 2019, then plummeted by 238.3% in 2023.
  • Over the past 5 years, BeOne Medicines' Long-Term Deferred Tax (Quarter) stood at $37.9 million in 2019, then soared by 74.07% to $66.0 million in 2020, then soared by 61.98% to $106.8 million in 2021, then skyrocketed by 1846.59% to $2.1 billion in 2022, then decreased by 2.38% to $2.0 billion in 2023.
  • Its Long-Term Deferred Tax stands at $2.0 billion for Q4 2023, versus $2.1 billion for Q4 2022 and $103.4 million for Q2 2022.